Pfizer PFE Biopharma — Restructuring cost incurred to date

Similar metrics at other companies

ATRPharma — Restructuring initiatives

$5K-97.4%

TMOLaboratory Products and Biopharma Services — Restructuring and other costs

$33M—

IFFHealth & Biosciences — Restructuring Charges

$2M-33.3%

CPBCorporate — Restructuring and Related Cost, Cost Incurred to Date

$34M+183%

RVTYLife Sciences — Restructuring and Other Costs (Income)

$3.23M+27.7%

TEC

TECHCorporate — Restructuring Charges

$688K+136%

Questions, answered.

What is Pfizer's biopharma — restructuring cost incurred to date?

Pfizer (PFE) reported biopharma — restructuring cost incurred to date of $3.3B in Q1 2026.

How has Pfizer's biopharma — restructuring cost incurred to date changed year-over-year?

Pfizer's biopharma — restructuring cost incurred to date increased by 22.2% year-over-year, from $2.7B to $3.3B.

What is the long-term trend for Pfizer's biopharma — restructuring cost incurred to date?

Over 3 years (2022 to 2025), Pfizer's biopharma — restructuring cost incurred to date has grown at a 38.1% compound annual growth rate (CAGR), from $4.36B to $11.5B.

What does biopharma — restructuring cost incurred to date mean?

The cumulative financial impact of restructuring activities already executed within the biopharmaceutical segment. It reflects the actual cash or non-cash charges recognized on the income statement due to organizational realignment.